Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Neovacs    ALNEV   FR0004032746

NEOVACS (ALNEV)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
12/06/2017 12/07/2017 12/08/2017 12/11/2017 12/12/2017 Date
0.52(c) 0.51(c) 0.56(c) 0.6(c) 0.58 Last
313 340 180 530 2 613 229 3 226 533 4 472 177 Volume
-3.70% -1.92% +9.80% +7.14% -3.33% Change
More quotes
Financials (€)
Sales 2017 4,60 M
EBIT 2017 -2,97 M
Net income 2017 -
Debt 2017 -
Yield 2017 -
Sales 2018 14,0 M
EBIT 2018 -1,71 M
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 8,04x
Capi. / Sales2018 2,64x
Capitalization 37,0 M
More Financials
Company
Neovacs SA is a biotechnology company which engages in the development of active immunotherapies for treating auto-immune, inflammatory and cancerous diseases.It focuses on the development of Tumor Necrosis Factor-Kinoid for treating Crohn's disease and rheumatoid polyarthritis and... 
More about the company
Latest news on NEOVACS
09:54a NEOVACS : Announces positive results of preclinical study for...
07:03a NEOVACS : ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY FOR IFNalpha KINOID IN..
07:02a NEOVACS : ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY FOR IFNalpha KINOID IN..
12/06 Systemic Lupus Erythematosus (SLE) – Market Is Expected to Grow with Up..
11/28 NEOVACS : announces free allocations of redeemable share...
10/30 ERRATUM : Neovacs provides business update and announces half-year 2017 financia..
10/27 NEOVACS : Provides business update and announces half-year 2017...
10/27 NEOVACS : Provides business update and announces half-year 2017 financial result..
10/17NEOVACS SA : half-yearly earnings release
09/26 NEOVACS : Publication du nombre d'actions et droits de vote au 30 juin 2017
More news
Sector news : Biotechnology & Medical Research - NEC
12:46p Sanofi investors hungry for drug progress and deal news
10:43a M&A dominates Europe share trading as oil leads gains
12/09 Tax-loss selling to pressure 2017's losers in December
11/30 GENMAB : and J&J 'love' partnership as some ponder takeover
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
More sector news : Biotechnology & Medical Research - NEC
Chart NEOVACS
Duration : Period :
Neovacs Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Technical analysis trends NEOVACS
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 3,07 €
Spread / Average Target 411%
Managers
NameTitle
Miguel Sieler Chief Executive Officer & Director
Jean-Jacques Bertrand Chairman
Géraldine Grouard-Vogel Chief Scientific Officer
Thérèse Croughs Chief Medical Officer
Daniel Zagury Director
Sector and Competitors
1st jan.Capitalization (M$)
NEOVACS-30.86%44
CELLTRION, INC.--.--%23 085
IQVIA HOLDINGS INC32.70%21 148
INCYTE CORPORATION-5.43%20 523
LONZA GROUP57.44%19 299
ALNYLAM PHARMACEUTICALS, INC.243.83%12 606